Abstract
Five new organometallic Ru(II) compounds (VI-X) with the general formula Ru(eta(6)-arene)(N,N)CIPF6, where arene-N,N correspond to methylisoeugenol-bipyridine (VI); anethole-bipyridine (VII); methylisoeugenol-ethylenediamine (VIII); anethole-ethylenediamine (IX) and methylisoeugenol-1,2-diaminobenzene (X), have been synthesized, fully characterized and biologically evaluated in vitro. The reaction conditions based on the reduction of Ru(1,5-COD)Cl-2(n) in situ with methyleugenol and estragole, which are natural ligands, induced an alkene isomerization on the allylic substituent of coordinated arenes. The Ru(II)-arene bond formation and isomerization of the C=C bond on the allyl substituent was confirmed using 1H NMR spectroscopy; this result was validated for compound VIII by X-ray diffraction. An XRD analysis revealed the presence of both enantiomers of the complex in the single-crystal. Compounds IX and X exhibited a better cytotoxic activity in vitro than carboplatin, which is a commercial drug, against three human tumor cell lines (MCF-7, PC-3 and HT-29).
- 2
- allyl
- bioorganometallic,
- bond
- cancer,
- complexes,
- cytotoxicity,
- diastereomers,
- dqcauchile
- drugs,
- isomerization,
- natural
- ovarian
- oxaliplatin,
- products,
- ru(ii)
- ruthenium,
- single-crystal,
- tumor-models,
Users
Please
log in to take part in the discussion (add own reviews or comments).